Assessment of Duration of Metabolic Effect of a Single Bolus of Subcutaneous Injected Lantus [insulin glargine] Compared to NPH-Insulin (Protaphan) [insulin suspension isophane] in Patients With Type 2 Diabetes

Trial Profile

Assessment of Duration of Metabolic Effect of a Single Bolus of Subcutaneous Injected Lantus [insulin glargine] Compared to NPH-Insulin (Protaphan) [insulin suspension isophane] in Patients With Type 2 Diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Nov 2007

At a glance

  • Drugs Insulin glargine; Insulin suspension isophane
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Sanofi
  • Most Recent Events

    • 16 Nov 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top